GPT and rheumatoid arthritis: The observed rate of hepatotoxicity (ALT >100 IU/mL) in our RA cohort of HBV carriers, isolated HBcAb and resolved HBV infection was 1.9% within 12 months of biologic and nonbiologic DMARD initiation, with no serious liver-related sequelae (death, hospitalization, liver transplant) reported as a consequence of treatment for RA.